Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.33 |
| ▸ | MMP3 | P08254 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272869 | 0.79 | MAPT (0.41) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL19776046 | 0.79 | MAPT (0.41) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL25634004 | 0.79 | MAPT (0.41) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL18738639 | 0.79 | MMP2 (0.34) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL19703918 | 0.78 | MMP2 (0.36) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL1941442 | 0.75 | TDP1 (0.43) | SLC22A6TDP1MAPTPGDSMN1; SMN2 | |
| SCHEMBL8853350 | 0.75 | TDP1 (0.43) | SLC22A6TDP1MAPTPGDSMN1; SMN2 | |
| SCHEMBL1941444 | 0.75 | TDP1 (0.43) | SLC22A6TDP1MAPTPGDSMN1; SMN2 | |
| SCHEMBL13082195 | 0.75 | EPHX1 (0.35) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL25992667 | 0.73 | CCKBR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | MMP2 2180/4885MMP3 3207/4885MMP1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.